Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing
暂无分享,去创建一个
Yu Zhang | Y. Ruan | Xiaodong Song | Zhiwen Xie | Tiewen Li | Xuhui Fan | Zeng Zhou | Yichen Zhang
[1] A. Clayton,et al. Cancer-Associated Fibroblast Heterogeneity, Activation and Function: Implications for Prostate Cancer , 2022, Biomolecules.
[2] S. Herrell,et al. Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease , 2022, Nature Communications.
[3] R. Zhou,et al. BCAM Deficiency May Contribute to Preeclampsia by Suppressing the PIK3R6/p-STAT3 Signaling , 2022, Hypertension.
[4] Yongjie Zhang,et al. Characterization of cancer-related fibroblasts (CAF) in hepatocellular carcinoma and construction of CAF-based risk signature based on single-cell RNA-seq and bulk RNA-seq data , 2022, Frontiers in Immunology.
[5] Huasong Huo,et al. Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies , 2022, Prostate Cancer and Prostatic Diseases.
[6] J. Qiu,et al. Construction and Verification of a Fibroblast-Related Prognostic Signature Model for Colon Cancer , 2022, Frontiers in Genetics.
[7] H. Klocker,et al. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer , 2022, Molecular Cancer.
[8] N. Erez,et al. Cancer-associated fibroblasts in the single-cell era , 2022, Nature Cancer.
[9] J Zhang,et al. Bioinformatic analysis of cancer-associated fibroblast related gene signature as a predictive model in clinical outcomes and immune characteristics of gastric cancer , 2022, Annals of translational medicine.
[10] J. Schlom,et al. Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication , 2022, The Journal of clinical investigation.
[11] Xiang Zhang,et al. circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis , 2022, Molecular cancer.
[12] C. Xue,et al. More Than Just Cleaning: Ubiquitin-Mediated Proteolysis in Fungal Pathogenesis , 2021, Frontiers in Cellular and Infection Microbiology.
[13] Chen Liang,et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives , 2021, Molecular Cancer.
[14] Hua Li,et al. Bisphenol S promotes the progression of prostate cancer by regulating the expression of COL1A1 and COL1A2. , 2021, Toxicology.
[15] R. Kalluri,et al. Clinical and therapeutic relevance of cancer-associated fibroblasts , 2021, Nature Reviews Clinical Oncology.
[16] Jing Yu,et al. Cancer-Associated Fibroblasts Promote Vascular Invasion of Hepatocellular Carcinoma via Downregulating Decorin-integrin β1 Signaling , 2021, Frontiers in Cell and Developmental Biology.
[17] Robert F. Gruener,et al. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data , 2021, Briefings Bioinform..
[18] Min Lu,et al. Downregulation of tumor‐derived exosomal miR-34c induces cancer‐associated fibroblast activation to promote cholangiocarcinoma progress , 2021, Cancer cell international.
[19] Samantha M. Carlisle,et al. Homeostatic functions of monocytes and interstitial lung macrophages are regulated via collagen domain-binding receptor LAIR1. , 2021, Immunity.
[20] S. Nakajima,et al. Stromal expression of cancer-associated fibroblast-related molecules, versican and lumican, is strongly associated with worse relapse-free and overall survival times in patients with esophageal squamous cell carcinoma , 2021, Oncology letters.
[21] E. Puré,et al. Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy , 2020, eLife.
[22] Jing Wang,et al. Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion , 2020, Nature Communications.
[23] Yifeng Jing,et al. Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis , 2020, Journal of Experimental & Clinical Cancer Research.
[24] T. Rebbeck,et al. Computationally Derived Image Signature of Stromal Morphology Is Prognostic of Prostate Cancer Recurrence Following Prostatectomy in African American Patients , 2020, Clinical Cancer Research.
[25] A. Ganesan,et al. Targeting B7‐1 in immunotherapy , 2020, Medicinal research reviews.
[26] Hao Li,et al. Broadly conserved roles of TMEM131 family proteins in intracellular collagen assembly and secretory cargo trafficking , 2020, Science Advances.
[27] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[28] M. Yao,et al. Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis , 2019, World Journal of Urology.
[29] P. Albers,et al. Prospective comparison of whole-body MRI and 68Ga-PSMA PET/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[30] H. G. van der Poel,et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. , 2019, European urology.
[31] X. Liu,et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.
[32] K. Iguchi,et al. Interleukin‐6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation , 2018, The Prostate.
[33] S. Barry,et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer , 2018, Nature.
[34] Paul Hoffman,et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.
[35] M. Dunning,et al. Identification of potential therapeutic targets in prostate cancer through a cross‐species approach , 2018, EMBO molecular medicine.
[36] R. Mehra,et al. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. , 2017, European urology.
[37] I. Mills,et al. Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] Yongrui Piao,et al. Analysis of Tim-3 as a therapeutic target in prostate cancer. , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
[39] M. Rubin,et al. Inherited determinants of early recurrent somatic mutations in prostate cancer , 2017, Nature Communications.
[40] D. Neal,et al. Asporin is a stromally expressed marker associated with prostate cancer progression , 2017, British Journal of Cancer.
[41] P. Laurent-Puig,et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.
[42] J. Sosman,et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.
[43] Lisa U. Magnusson,et al. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment , 2016, The Prostate.
[44] S. Turley,et al. Immunological hallmarks of stromal cells in the tumour microenvironment , 2015, Nature Reviews Immunology.
[45] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[46] Jennifer R. Rider,et al. Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer , 2015, Clinical Cancer Research.
[47] Pierre Drion,et al. Asporin Is a Fibroblast-Derived TGF-β1 Inhibitor and a Tumor Suppressor Associated with Good Prognosis in Breast Cancer , 2015, PLoS medicine.
[48] S. Vowler,et al. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study , 2015, EBioMedicine.
[49] G. Getz,et al. Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.
[50] Justin Guinney,et al. GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.
[51] A. Anderson. Tim-3, a negative regulator of anti-tumor immunity. , 2012, Current opinion in immunology.
[52] Renaud Gaujoux,et al. A flexible R package for nonnegative matrix factorization , 2010, BMC Bioinformatics.
[53] R. Tibshirani. The lasso method for variable selection in the Cox model. , 1997, Statistics in medicine.
[54] D. Gfeller,et al. EPIC: A Tool to Estimate the Proportions of Different Cell Types from Bulk Gene Expression Data. , 2020, Methods in molecular biology.